Inhibition of human B cell activation by gold compounds

Clinical Immunology and Immunopathology

Volumn 81, Issue 2, 1996, Pages 175-181

  Hirohata, Shunsei ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; BACTERIAL ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; SODIUM CHLORIDE; TRANSFERRIN RECEPTOR;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; GOLD THERAPY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STAPHYLOCOCCUS AUREUS;

EID: 0030296586     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0174     Document Type: Article

References (32)

1. 1. Huskisson, E. C., Specific therapy for rheumatoid arthritis. Rheumatol. Rehabil. 15, 133-135, 1976.
2. 2. Wright, V., and Amos, R., Do drugs change the course of rheumatoid arthritis? Br. Med. J. 280, 964-966, 1980.
3. 3. Harth, M., Mechanism of action of disease modifying antirheumatic drugs. J. Rheumatol. 19 (Suppl. 32), 100-103, 1992.
4. 4. Waaler, E., On the occurrence of factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol. Microbiol. Scand. 17, 172-178, 1940.
5. 5. Smiley, J. D., Sachs, C., and Ziff, M., In vitro synthesis of immunoglobulins by rheumatoid synovial membrane. J. Clin. Invest. 47, 624-632, 1968.
6. 6. Winchester, R. J., Agnello, V., and Kunkel, H. G., Gammaglobulin complexes in synovial fluids of patients with rheumatoid arthritis. II. Partial characterization and relationship to lowered complement levels. Clin. Exp. Immunol. 6, 689-706, 1970.
7. 7. Tanimoto, K., Cooper, N. R., Johnson, J. S., and Vaughan, J. H., Complement fixation by rheumatoid factor. J. Clin. Invest. 55, 437-445, 1975.
8. 8. Lorber, A., Simon, T., Leeb, J., Peter, A., and Wilcox, S., Chrysotherapy: Suppression of immunoglobulin synthesis. Arthritis Rheum. 21, 785-791, 1978.
9. 9. Research Subcommittee of the Empire Rheumatism Council, Gold therapy in rheumatoid arthritis: Report of a multicenter controlled trial. Ann. Rheum. Dis. 19, 95-119, 1960.
10. 10. Hashimoto, K., Whitehurst, C. E., Matsubara, T., Hirohata, K., and Lipsky, P. E., Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C. J. Clin. Invest. 89, 1839-1848, 1992.
11. 11. Lipsky, P. E., and Ziff, M., Inhibition of antigen-and mitogen-induced human lymphocyte proliferation by gold compounds. J. Clin. Invest. 59, 455-466, 1977.
12. 12. Matsubara, T., and Ziff, M., Inhibition of human endothelial cell proliferation by gold compounds. J. Clin. Invest. 79, 1440-1446, 1987.
13. 13. Newman, P. M., To, S. S. T., Robinson, B. G., Hyland, V. J., and Schrieber, L., Effect of gold sodium thiomalate and its thiomalate component on the in vitro expression of endothelial cell adhesion molecules. J. Clin. Invest. 94, 1864-1871, 1994.
14. 14. Thiele, D. L., Kurosaka, M., and Lipsky, P. E., Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: Delineation by its sensitivity to the lysosomotrophic agent, L-leucine methyl ester. J. Immunol. 131, 2282-2290, 1983.
15. 15. Hirohata, S., Yamada, A., and Inoue, T., A sensitive and simple method for determination of IgM in cerebrospinal fluid by a solid-phase enzyme immunoassay: Comparison of two different methods. J. Neurol. Sci. 67, 115-118, 1985.
16. 16. Geppert, T. D., and Lipsky, P. E., Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. J. Immunol. 138, 1660-1666, 1987.
17. 17. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63, 1983.
18. 18. Hirohata, S., and Oka, H., Modulation of T cell production of interferon-γ by human monocytes: Effect of engagement of CD14 on monocytes. Cell. Immunol. 151, 270-282, 1993.
19. 19. Cotner, T., Williams, J. M., Christenson, L., Shapiro, H. M., Strom, T. B., and Strominger, J., Simultaneous flowcytometric analysis of human T cell activation antigen expression and DNA content. J. Exp. Med. 157, 461-472, 1983.
20. 20. Kehrl, J. H., Muraguchi, A., and Fauci, A. S., Differential expression of cell activation markers after stimulation of resting human B lymphocytes. J. Immunol. 132, 2857-2861, 1984.
21. 21. Dahl, S. L., Coleman, M. L., Williams, H. J., Alz-Smith, M., Kay, D. R., Paulus, H. E., Weinstein, A., and Kaplan, S., Lack of correlation between blood gold concentrations and clinical response in patients with definite or classic rheumatoid arthritis receiving auranofin or gold sodium thiomalate. Arthritis Rheum. 28, 1211-1218, 1985.
22. 22. Hirohata, S., and Lipsky, P. E., Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 37, 942-950, 1994.
23. 23. Hirohata, S., and Yanagida, T., Inhibition of expression of cyclin A in human B cells by an immunosuppressant mizoribine. J. Immunol. 155, 5175-5183, 1995.
24. 24. Shaw, C. F., The mammalian biochemistry of gold: An inorganic perspective of chrysotherapy. Inorg. Perspect. Biol. Med. 2, 287-355, 1979.
25. 25. Shaw, C. F., The protein chemistry of antiarthritic gold (I) thiolates and related complexes. Comments Inorg. Chem. 8, 233-267, 1989.
26. 26. Jimenez, J. S., Kupfer, A., Gani, V., and Shaltiel, S., Salt-induced conformational changes in the catalytic subunit of adenosine cyclic 3′,5′-phosphate dependent protein kinase. Use for establishing a connection between one sulfhydryl group and the γ-P subsite in the ATP site of this subunit. Biochemistry 21, 1623-1630, 1982.
27. 27. Parker, P. J., Coussens, L., Totty, N., Rhee, L., Young, S., Chen, E., Stabel, S., Waterfield, M. D., and Ullrich, A., The complete primary structure of protein kinase C: The major phorbol ester receptor. Science 233, 853-859, 1986.
28. 28. Harding, C. V., and Unanue, E. R., Antigen processing and intracellular Ia. Possible roles of endocytosis and protein synthesis in Ia function. J. Immunol. 142, 12-19, 1989.
29. 29. Griem, P., Takahashi, K., Kaibacher, H., and Gleichmann, E., The antirheumatic drug disodium aurothiomalate inhibits CD4+ T cell recognition of peptides containing two or more cysteine residues. J. Immunol. 155, 1575-1587, 1995.
30. 30. Paulus, H. E., Machleder, H. I., Levine, S., Yu, D. T. Y., and MacDonald, N. S., Lymphocyte involvement in rheumatoid arthritis: Studies during thoracic duct drainage. Arthritis Rheum. 20, 1249-1262, 1977.
31. 31. Gaston, J. S. H., Strober, S., Solovera, J. J., Gandour, D., Lane, N., Schurman, D., Hoppe, R. T., Chin, R. C., Eugui, E. M., Vaughan, J. H., and Allison, A. C., Dissection of the mechanisms of immune injury in rheumatoid arthritis, using total lymphoid irradiation. Arthritis Rheum. 31, 21-30, 1988.
32. 32. Reiter, C., Kakavand, B., Rieber, E. P., Schattenkirchner, M., Riethmüller, G., and Krüger, K., Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum. 34, 525-536, 1991.